Due to the addiction of CRC on both KRAS/MAPK/ERK- and PIK3CA/AKT-signaling pathways and the important role of p130CAS as an integrator of signaling pathway activities, we were interested in a possible role of p130Cas as a biomarker as wells as a target for CRC-specific chemotherapy in CRC. The gene discussed is KRAS; the disease is colorectal carcinoma.